Perspectum Lands Top Spot in Alantra Pharma Fast 50 Rankings. Read more
Perspectum Awarded Multi-Million Euro Grant to Begin RADIcAL Trial
- January 13, 2017
- Grants, LiverMultiScan, News, Press Releases
Thousands of patients in Europe with liver disease could be saved from having painful and expensive needle biopsies in the future, after a multi-million Euro grant was awarded to a consortium of hospitals to use a faster and safer MRI called LiverMultiScan, developed by Perspectum Diagnostics.
Fuelled by rising levels of obesity, Non-Alcoholic Fatty Liver Disease (NAFLD) affects up to a quarter of the European population and left untreated can lead to cirrhosis and liver failure. The historic method of diagnosing NAFLD is by liver biopsy, which in addition to being costly and painful, samples only a tiny fraction (1/50,000th) of the liver. LiverMultiScan, which is being showcased at the forthcoming International Liver Congress in Amsterdam (April 19 – 23rd) is a non-invasive alternative which accurately measures liver fat and other metrics, and can help doctors detect early disease.
“A cost-effective tool for non-invasive liver tissue characterisation would be a major step forward in the treatment of patients with liver diseases such as non-alcoholic fatty liver disease,” explains Dr. Minneke Coenraad from Leiden University Medical Centre, one of the investigators leading the study.
Supported by the Horizon 2020 SME instrument, the RADIcAL trial (Rapid Assessment and Diagnosis in Chronic Adult Liver disease) will compare the cost of patient care using liver biopsy with that of using LiverMultiScan. 2,000 patients suspected of a diagnosis of NAFLD will be recruited to centres in Germany, the Netherlands and Portugal. Each patient will be randomised to either follow the current diagnostic pathway with biopsy, or to have early access to state-of-the-art MRI with LiverMultiScan, to determine the presence and extent of disease. At the end of the trial, the cost-effectiveness and patient-reported outcome measures of the two diagnostic pathways will be compared.
Dr Rajarshi Banerjee, CEO of Perspectum Diagnostics, says “We are delighted that the H2020 funding body recognises the enormous potential for LiverMultiScan to replace unnecessary biopsies. There is a real opportunity here, not only to make significant economic savings at a time when all health services are under pressure, but also to reduce the number of patients having to undergo what can be a stressful and painful procedure.”
Doctors and patients can learn more about LiverMultiScan and the RADiCAL MRI technology by visiting Booth 163 at the International Liver Congress in Amsterdam, April 19-23rd, or visiting https://www.perspectum-diagnostics.com.
LiverMultiscan was introduced in Europe and the U.S. as a research device in 2014. It is now installed in leading medical institutions on three continents. The technology offers a quantitative liver assessment in a safe, non-invasive 15-minute MRI scan. LiverMultiScan is manufactured by Mirada Medical, and has CE-marking and FDA-clearance.
About Perspectum Diagnostics
Perspectum Diagnostics is a medical imaging company founded by scientists and physicians from the University of Oxford. It has pioneered the use of quantitative magnetic resonance imaging to accurately detect and measure biomarkers of liver disease.